M.E.A.C. Engineering v. Solventum: NPWT Patent Dispute Dismissed With Prejudice
M.E.A.C. Engineering LTD filed suit against Solventum Corporation in the Western District of Texas, asserting two patents covering negative pressure wound therapy technology against multiple 3M V.A.C. product lines. The case resolved via stipulated dismissal with prejudice under Rule 41(a)(1)(A)(ii) after 368 days, with each party bearing its own costs.
NPWT patent claims against 3M V.A.C. product line end in mutual exit
M.E.A.C. Engineering LTD, a patent holder in the negative pressure wound therapy space, filed suit against Solventum Corporation on October 5, 2023 in the Western District of Texas before Judge Xavier Rodriguez. The complaint asserted two U.S. patents — US8506554B2 and US8858534B2 — against a broad portfolio of Solventum’s 3M-branded NPWT products, including the ActiV.A.C., Prevena Plus 125, V.A.C. RX4, V.A.C. Simplicity, V.A.C. Ulta 4, V.A.C. FREEDOM, and the SensaT.R.A.C. Pad.
The case closed on October 7, 2024, exactly 368 days after filing, through a stipulated dismissal with prejudice filed pursuant to Fed. R. Civ. P. 41(a)(1)(A)(ii). The parties jointly agreed that dismissal would be with prejudice and that each side would bear its own expenses, costs, and attorneys’ fees. A dismissal with prejudice is a final adjudication on the merits, meaning M.E.A.C. is permanently barred from reasserting the same patent claims against Solventum in any future proceeding.
The 368-day timeline suggests the case progressed through at least initial motion practice or claim construction preparation before the parties reached resolution. The mutual cost-bearing arrangement — rather than a fee award to either side — is consistent with a negotiated resolution, possibly involving a license, cross-license, or commercial understanding. The public record does not disclose any settlement terms, financial consideration, or licensing arrangement, and none can be confirmed from available filings.
Filing to Voluntary dismissal in 368 days
368 days — above the median for W.D. Texas patent cases dismissed before trial
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a)(1)(A)(ii) — stipulated dismissal by both parties
A dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) requires a signed stipulation from all appearing parties. Unlike a unilateral voluntary dismissal, this route demands Solventum’s agreement, suggesting the exit was negotiated. The ‘with prejudice’ designation converts the dismissal into a final judgment on the merits — equivalent in preclusive effect to a court decision against the plaintiff.
Stipulated — both parties consentedM.E.A.C. permanently relinquishes claims against Solventum
By agreeing to dismissal with prejudice, M.E.A.C. Engineering forfeits any right to reassert US8506554B2 or US8858534B2 against Solventum or its 3M V.A.C. product lines in future litigation. This is a significant concession for a patent holder unless offset by undisclosed commercial terms. The public record is silent on whether any license fee or settlement consideration was exchanged.
Claims extinguished against SolventumSolventum secures permanent dismissal of NPWT patent threat
Solventum, represented by Honigman LLP and Norton Rose Fulbright, exits with a with-prejudice dismissal — the strongest possible litigation closure short of a court ruling of non-infringement or invalidity. The 3M V.A.C. product portfolio, including the SensaT.R.A.C. Pad and multiple V.A.C. system variants, is shielded from these specific patent claims. Each-party-bears-own-costs is commercially standard in negotiated exits of this type.
Product line cleared of these claimsNPWT competitors should note: patents remain in force against others
A dismissal with prejudice binds only M.E.A.C. and Solventum. US8506554B2 and US8858534B2 remain valid, enforceable patents that M.E.A.C. could assert against other NPWT manufacturers or device distributors. Companies operating in the negative pressure wound therapy space — particularly those with products functionally comparable to the V.A.C. system — face continued exposure and should evaluate freedom-to-operate positions against both asserted patents.
Patents enforceable against third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | M.E.A.C. ENGINEERING LTD | Company | NPWT patent licensing entity — holder of US8506554B2 and US8858534B2Search in Eureka ↗ |
| Defendant | Solventum Corporation | Company | Solventum Corporation — medical technology spinoff, manufacturer of 3M V.A.C. NPWT systemsSearch in Eureka ↗ |
| Plaintiff counsel | Erik Nelson Lund | Attorney | Counsel for M.E.A.C. ENGINEERING LTDSearch in Eureka ↗ |
| Plaintiff counsel | Joseph J. Zito | Attorney | Counsel for M.E.A.C. ENGINEERING LTDSearch in Eureka ↗ |
| Plaintiff law firm | Dnl Zito Castellano | Law Firm | Representing M.E.A.C. ENGINEERING LTDSearch in Eureka ↗ |
| Plaintiff law firm | Dnl Zito | Law Firm | Representing M.E.A.C. ENGINEERING LTDSearch in Eureka ↗ |
| Defendant counsel | Aimee Vidaurri | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Deborah J. Swedlow | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Michael William O’Donnell | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Ron N. Sklar | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Vikram A. Mathrani | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant law firm | Honigman LLP | Law Firm | Representing Solventum CorporationSearch in Eureka ↗ |
| Defendant law firm | Norton Rose Fulbright US LLP | Law Firm | Representing Solventum CorporationSearch in Eureka ↗ |
| Presiding judge | Judge Xavier Rodriguez | Judge | Texas Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language — ‘The parties agree that dismissal shall be with prejudice. Each party shall bear its own expenses, costs, and attorneys’ fees’ — reflects a bilaterally negotiated exit with no fee-shifting. The with-prejudice designation carries full res judicata effect for M.E.A.C.’s claims under US8506554B2 and US8858534B2 against Solventum. Crucially, the absence of any court ruling on validity or infringement means the patents survive intact and enforceable against all other parties in the NPWT market.
US8506554B2 & US8858534B2 — negative pressure wound therapy systems
US8506554B2 (Application No. US11/989297) and US8858534B2 (Application No. US13/917865) both cover technology in the negative pressure wound therapy domain — a field involving the application of sub-atmospheric pressure to wounds to promote healing, manage exudate, and reduce infection risk. The staggered application numbers suggest a continuation or divisional relationship, with the later application (US13/917865) potentially expanding or refining claims established in the earlier filing. Both patents are granted U.S. utility patents with full enforceability as of the filing date of this action.
NPWT is a high-value medical device segment dominated by a small number of commercial platforms, of which 3M’s V.A.C. system is among the most widely deployed globally. Patents in this space typically cover wound interface components, pressure regulation circuitry, fluid collection mechanisms, and sensor integration — all of which are implicated by the nine Solventum products named in this action. For competitors developing portable or disposable NPWT systems, these patents represent active enforcement risk, particularly given M.E.A.C.’s demonstrated willingness to litigate against a major commercial incumbent.
Should your NPWT product be cleared against US8506554B2 and US8858534B2?
Any company developing, manufacturing, or commercialising negative pressure wound therapy devices — including portable wound care systems, disposable canisters, pressure-regulating pads, or integrated sensor assemblies — should treat US8506554B2 and US8858534B2 as active FTO concerns. M.E.A.C.’s willingness to assert both patents against a nine-product portfolio from a major medical device incumbent confirms these are aggressively enforced assets. The with-prejudice dismissal does not limit M.E.A.C.’s rights against any other party.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map product features against the independent and dependent claims of both asserted patents, identify prior art that may limit claim scope, and flag continuation risk from the staggered application timeline. Eureka can also surface related M.E.A.C. patent holdings and prosecution history signals that may indicate broadened claim strategies in pending applications — critical intelligence before a product launch in the NPWT space.
Run a freedom-to-operate analysis on US8506554B2 to assess your product’s exposure
Run FTO in Eureka →Similar NPWT and wound care patent cases in W.D. Texas
Cases involving negative pressure wound therapy patents litigated in the Western District of Texas — including comparable infringement actions against medical device product lines.
What this case signals for the NPWT and wound care IP landscape
A with-prejudice stipulated dismissal in a multi-product NPWT dispute carries meaningful implications for patent strategy across the wound care device sector.
With-prejudice exits in W.D. Texas often signal undisclosed licensing
When a patent plaintiff agrees to dismissal with prejudice — especially after nearly a full year of litigation — it is typically inconsistent with a simple walk-away. The mutual cost-bearing structure and bilateral consent required by Rule 41(a)(1)(A)(ii) suggest a negotiated commercial resolution, most likely involving licensing terms not reflected in any public filing. Practitioners monitoring M.E.A.C.’s assertion strategy should treat this as a potential licensing precedent.
Broad product scope signals portfolio-level licensing ambition
M.E.A.C. named nine distinct Solventum products in its complaint — spanning portable, stationary, and abdominal NPWT configurations. This breadth is consistent with a licensing campaign rather than targeted infringement enforcement. NPWT device manufacturers with comparable product lines should assess whether M.E.A.C.’s two asserted patents cover their architectures, particularly systems using negative pressure regulation and fluid management methods.
M.E.A.C. v Solventum — key questions answered
M.E.A.C. Engineering LTD filed a patent infringement action against Solventum Corporation in the Western District of Texas on October 5, 2023, asserting US8506554B2 and US8858534B2 against nine 3M-branded NPWT products. The case was dismissed with prejudice by stipulation under Rule 41(a)(1)(A)(ii) on October 7, 2024, after 368 days, with each party bearing its own costs.
Dismissal with prejudice operates as a final adjudication on the merits. M.E.A.C. Engineering is permanently barred from asserting US8506554B2 or US8858534B2 against Solventum Corporation or its 3M V.A.C. product lines in any future proceeding. The patents themselves remain valid and fully enforceable against all other third parties in the NPWT market.
The complaint identified nine products: the 3M ActiV.A.C. Therapy System, 3M Prevena Plus 125 Therapy Unit, 3M V.A.C. RX4 Therapy System, 3M V.A.C. Simplicity Therapy System, 3M V.A.C. Ulta 4 Therapy System, the V.A.C. FREEDOM Therapy System, the SensaT.R.A.C. Pad, and the broader Negative Pressure Wound Therapy / V.A.C. platform. The SensaT.R.A.C. Pad is included with all 3M V.A.C. and 3M AbThera Dressings.
No. The stipulated dismissal expressly states that each party shall bear its own expenses, costs, and attorneys’ fees. No fee-shifting was ordered or agreed upon. This mutual cost-bearing arrangement is commercially standard in negotiated patent litigation exits but does not preclude undisclosed financial terms between the parties.
No. A with-prejudice dismissal binds only the parties to that stipulation — M.E.A.C. Engineering and Solventum Corporation. US8506554B2 and US8858534B2 remain valid, issued U.S. patents fully enforceable against any other manufacturer, distributor, or user of NPWT technology that falls within the patents’ claim scope. Companies with functionally similar wound therapy systems should independently assess their FTO exposure.
PatSnap Eureka searches patents and litigation data to answer instantly.